Vivoryon Therapeutics NV (FRA:05Y) FCF Margin % : 48.70% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Vivoryon Therapeutics NV FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Vivoryon Therapeutics NV's Free Cash Flow for the six months ended in Dec. 2023 was €-1.76 Mil. Vivoryon Therapeutics NV's Revenue for the six months ended in Dec. 2023 was €-3.62 Mil. Therefore, Vivoryon Therapeutics NV's FCF Margin % for the quarter that ended in Dec. 2023 was 48.70%.

As of today, Vivoryon Therapeutics NV's current FCF Yield % is -65.59%.

The historical rank and industry rank for Vivoryon Therapeutics NV's FCF Margin % or its related term are showing as below:

FRA:05Y' s FCF Margin % Range Over the Past 10 Years
Min: -104.84 Med: 252.21 Max: 609.25
Current: 609.25

During the past 13 years, the highest FCF Margin % of Vivoryon Therapeutics NV was 609.25%. The lowest was -104.84%. And the median was 252.21%.

FRA:05Y's FCF Margin % is ranked better than
99.23% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs FRA:05Y: 609.25

Vivoryon Therapeutics NV FCF Margin % Historical Data

The historical data trend for Vivoryon Therapeutics NV's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivoryon Therapeutics NV FCF Margin % Chart

Vivoryon Therapeutics NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-104.84

609.25

Vivoryon Therapeutics NV Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-48.21	-	-	-	48.70

Competitive Comparison of Vivoryon Therapeutics NV's FCF Margin %

For the Biotechnology subindustry, Vivoryon Therapeutics NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivoryon Therapeutics NV's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Vivoryon Therapeutics NV's FCF Margin % falls into.

Vivoryon Therapeutics NV FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Vivoryon Therapeutics NV's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-22.055	/	-3.62
	=	609.25 %

Vivoryon Therapeutics NV's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.763	/	-3.62
	=	48.70 %

Vivoryon Therapeutics NV FCF Margin % Related Terms

Thank you for viewing the detailed overview of Vivoryon Therapeutics NV's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivoryon Therapeutics NV (FRA:05Y) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivoryon Therapeutics NV (FRA:05Y) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

VVY:Netherlands

Address

Weinbergweg 22, Halle, SN, DEU, 06120

Website

https://www.vivoryon.com

Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products include PQ912 and PQ1565. Geographically, the majority is from Greater China.

Vivoryon Therapeutics NV (FRA:05Y) Headlines

No Headlines